Aliases & Classifications for Keratosis

MalaCards integrated aliases for Keratosis:

Name: Keratosis 12 44 15 73
Actinic Keratosis 73
Hyperkeratosis 73

Classifications:



External Ids:

Disease Ontology 12 DOID:161
MeSH 44 D007642
NCIt 50 C34747

Summaries for Keratosis

Disease Ontology : 12 A skin disease characterized_by growth of keratin on the skin or mucous membranes.

MalaCards based summary : Keratosis, also known as actinic keratosis, is related to keratosis, seborrheic and keratosis follicularis spinulosa decalvans, and has symptoms including pruritus, exanthema and trichorrhexis invaginata. An important gene associated with Keratosis is MBTPS2 (Membrane Bound Transcription Factor Peptidase, Site 2), and among its related pathways/superpathways are Developmental Biology and Keratinization. The drugs Aminolevulinic acid and Imiquimod have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and kidney, and related phenotypes are Increased vaccinia virus (VACV) infection and cellular

Wikipedia : 76 Keratosis (from kerat- + -osis) is a growth of keratin on the skin or on mucous membranes stemming from... more...

Related Diseases for Keratosis

Diseases related to Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 255)
# Related Disease Score Top Affiliating Genes
1 keratosis, seborrheic 34.2 FGFR3 KRT10 PIK3CA
2 keratosis follicularis spinulosa decalvans 33.9 LRP1 MBTPS2 SAT1
3 keratosis follicularis spinulosa decalvans, x-linked 33.9 MBTPS2 SAT1
4 mal de meleda 32.5 KRT1 SERPINB7 SLURP1
5 palmoplantar keratosis 32.4 CTSC DSG1 DSP GJB2 KRT1 KRT9
6 punctate palmoplantar keratoderma 32.4 AAGAB KRT10
7 palmoplantar keratoderma, epidermolytic 31.8 FLG KRT1 KRT10 KRT9
8 striate palmoplantar keratoderma 31.4 CTSC DSG1 DSP KRT1 KRT10 SERPINB7
9 dermatosis papulosa nigra 31.2 FGFR3 PIK3CA
10 lichen planus 30.6 FLG IVL KRT10
11 acanthoma 30.4 KRT1 KRT10
12 alopecia 30.3 DSP GJA1 MBTPS2
13 keratoacanthoma 30.3 DSG1 FLG KRT10
14 porokeratosis 30.3 FGFR3 FLG IVL
15 nevus, epidermal 30.1 ATP2A2 FGFR3 KRT10 PIK3CA
16 discoid lupus erythematosus 29.8 FLG IVL KRT10
17 ichthyosis 29.8 FLG GJB2 KRT1 KRT10 MBTPS2 POMP
18 cellulitis 29.7 ATP2A2 DSG1 DSP
19 bullous pemphigoid 29.7 DSG1 DSP IVL
20 epidermolytic hyperkeratosis 29.7 FLG KRT1 KRT10 KRT9
21 ainhum 29.7 GJA1 GJB2
22 papilloma 29.6 FGFR3 FLG IVL KRT1 KRT10
23 cardiomyopathy, dilated, with woolly hair and keratoderma 29.6 DSG1 DSP GJA1
24 knuckle pads 29.4 GJA1 GJB2 KRT9
25 actinic keratosis 12.6
26 keratosis pilaris atrophicans 12.4
27 keratosis linearis with ichthyosis congenita and sclerosing keratoderma 12.4
28 inverted follicular keratosis 12.4
29 keratosis follicularis, dwarfism, and cerebral atrophy 12.4
30 keratosis follicularis spinulosa decalvans, autosomal dominant 12.2
31 vulvar seborrheic keratosis 12.2
32 vulvar inverted follicular keratosis 12.1
33 darier-white disease 12.1
34 inflamed seborrheic keratosis 12.1
35 keratosis palmoplantaris striata iii 12.1
36 keratosis palmoplantaris striata ii 12.1
37 papillon-lefevre syndrome 12.0
38 keratosis palmaris et plantaris with clinodactyly 12.0
39 keratosis, familial actinic 11.9
40 keratosis, focal palmoplantar and gingival 11.9
41 onychogryposis, pedal, with keratosis plantaris and coarse hair 11.9
42 circumscribed disseminated keratosis jadassohn lew type 11.9
43 keratosis palmoplantaris adenocarcinoma of the colon 11.9
44 palmoplantar keratoderma, punctate type ia 11.8
45 haim-munk syndrome 11.7
46 erythrokeratodermia variabilis et progressiva 1 11.7
47 tyrosinemia, type ii 11.7
48 ulerythema ophryogenesis 11.6
49 focal palmoplantar and gingival keratoderma 11.6
50 palmoplantar keratoderma i, striate, focal, or diffuse 11.4

Comorbidity relations with Keratosis via Phenotypic Disease Network (PDN):


Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Keratosis, Seborrheic

Graphical network of the top 20 diseases related to Keratosis:



Diseases related to Keratosis

Symptoms & Phenotypes for Keratosis

UMLS symptoms related to Keratosis:


pruritus, exanthema, trichorrhexis invaginata

GenomeRNAi Phenotypes related to Keratosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased vaccinia virus (VACV) infection GR00249-S 9.62 AAGAB ATP2A2 CTSC DSG1 DSP FGFR3

MGI Mouse Phenotypes related to Keratosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.85 ATP2A2 CTSC DSP FGFR3 GJA1 GJB2
2 growth/size/body region MP:0005378 9.73 ATP2A2 CTSC DSG1 DSP FGFR3 GJA1
3 integument MP:0010771 9.36 ATP2A2 CTSC DSG1 DSP FGFR3 GJA1

Drugs & Therapeutics for Keratosis

Drugs for Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 243)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
2
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99011-02-6 57469
3
Fluorouracil Approved Phase 4,Phase 3,Early Phase 1,Not Applicable 51-21-8 3385
4
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
5
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15307-86-5 3033
6
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
7
Alginic acid Approved, Investigational Phase 4 9005-32-7
8
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
9
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
10
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 2,Not Applicable 25122-46-7, 25122-41-2 5311051 32798
11
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2 185243-69-0
12
Terbinafine Approved, Investigational, Vet_approved Phase 4,Phase 2 91161-71-6 1549008 5402
13
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
14
Amorolfine Approved, Investigational Phase 4 78613-35-1
15
Itraconazole Approved, Investigational Phase 4,Phase 3 84625-61-6 55283
16
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
17
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
18
Petrolatum Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 8009-03-8
19
Hydrogen peroxide Approved, Vet_approved Phase 4,Phase 2 7722-84-1 784
20
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 69-72-7 338
21
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2 104987-11-3 445643 439492
22
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 46835353 6436030 5284616
23
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177
24
Menthol Approved Phase 4 2216-51-5 16666
25
Azathioprine Approved Phase 4 446-86-6 2265
26
Mycophenolic acid Approved Phase 4 24280-93-1 446541
27
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 11103-57-4, 68-26-8 445354
28
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1 50-14-6 5280793
29
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Not Applicable 1406-16-2
31 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Radiation-Protective Agents Phase 4,Phase 2
39 Sunscreening Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
41 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
43 Antimetabolites, Antineoplastic Phase 4,Phase 3,Early Phase 1,Not Applicable
44 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
49 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
50 Hormones Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 409)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
2 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
3 Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis Unknown status NCT01656226 Phase 4
4 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
5 Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
6 Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
7 Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
8 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
9 Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
10 Effects of Topical Diclofenac on Tumor Metabolism Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
11 Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
12 Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Laser Density for Actinic Keratosis Completed NCT03731988 Phase 4 lidocaine/prilocaine (5%) application;MAL application
13 Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage Completed NCT03697590 Phase 4 No curettage;Curettage
14 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT) Completed NCT01000636 Phase 4
15 Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses Completed NCT02251652 Phase 4 Ingenol Mebutate
16 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
17 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
18 Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
19 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
20 Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
21 Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
22 Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine;Polysporin
23 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
24 Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
25 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
26 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
27 PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
28 Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
29 Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients Completed NCT00599807 Phase 4
30 Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails Completed NCT01703325 Phase 4 0.1% triamcinolone , 0.05% clobetasol propionate ointment
31 Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept
32 Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
33 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
34 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4 Fibrate treatment
35 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
36 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Recruiting NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
37 Treatment of Photodamaged Skin of the décolleté Recruiting NCT03573076 Phase 4
38 Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy Active, not recruiting NCT02990221 Phase 4 Ingenol mebutate
39 IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis Active, not recruiting NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
40 An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses Active, not recruiting NCT03487588 Phase 4 A-101 Topical Solution
41 Daylight-PDT With MAL for AK and Photodamaged Skin Active, not recruiting NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
42 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
43 Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention Not yet recruiting NCT03642535 Phase 4 ALA
44 Menthol for PDT Pain Not yet recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
45 Apremilast and Moderate to Severe Chronic Hand Dermatitis Not yet recruiting NCT03741933 Phase 4 Apremilast 30mg
46 Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
47 Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
48 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
49 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
50 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus

Search NIH Clinical Center for Keratosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: keratosis

Genetic Tests for Keratosis

Anatomical Context for Keratosis

MalaCards organs/tissues related to Keratosis:

41
Skin, Testes, Kidney, Liver, Bone, Colon, Myeloid

Publications for Keratosis

Articles related to Keratosis:

(show top 50) (show all 1686)
# Title Authors Year
1
Efficacy Endpoints in Clinical Trials in Actinic Keratosis. ( 29916197 )
2018
2
Photodynamic therapy corrects abnormal cancer-associated gene expression observed in actinic keratosis lesions and induces a remodeling effect in photodamaged skin. ( 29779986 )
2018
3
Novel mutation in MBTPS2 causes keratosis follicularis spinulosa decalvans in a large Chinese family. ( 29951998 )
2018
4
A new dermoscopic algorithm for the differential diagnosis of facial lentigo maligna and pigmented actinic keratosis. ( 29620004 )
2018
5
Comparison of 10 efficient protocols for photodynamic therapy of actinic keratosis: How relevant are effective light dose and local damage in predicting the complete response rate at 3 months? ( 29667728 )
2018
6
Reflectance confocal microscopy: a crucial role for actinic keratosis treatment monitoring. ( 29846971 )
2018
7
Successful Treatment of Actinic Keratosis with Kanuka Honey. ( 29955399 )
2018
8
Arsenical keratosis secondary to Fowler solution. ( 29387754 )
2018
9
A multi-centre, open, investigator initiated phase IV clinical trial to evaluate the efficacy and safety of ingenol mebutate gel, 0.015% on the face and scalp, and 0.05% on the trunk and extremities, in Korean patients with actinic keratosis (PERFECT). ( 29355904 )
2018
10
Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy. ( 29920789 )
2018
11
MART-1-Labeled Melanocyte Density and Distribution in Actinic Keratosis and Squamous Cell Cancer in situ: Pagetoid Melanocytes are a Potential Source of Misdiagnosis as Melanoma in Situ. ( 29943494 )
2018
12
Multiple Pigmented Seborrheic Keratosis with Sebaceous Differentiation - A Case Report. ( 28272654 )
2018
13
Differential proteomic analysis of actinic keratosis, Bowen's disease and cutaneous squamous cell carcinoma by label-free LC-MS/MS. ( 29665991 )
2018
14
Treatment of Grade II and III Actinic Keratosis Lesions with a Film-Forming Medical Device Containing Sunscreen/Piroxicam 0.8% and a Retinoic Acid/Glycolic Gel: A Pilot Trial. ( 29855896 )
2018
15
Topical formulations of delta-aminolevulinic acid for the treatment of actinic keratosis: Characterization and efficacy evaluation. ( 29407554 )
2018
16
Desmoglein 4 Mutation Underlies Autosomal Recessive Keratosis Pilaris Atrophicans. ( 29796690 )
2018
17
Photodynamic therapy with the use of superluminescent diodes (sLED) in the treatment of actinic keratosis. ( 29684690 )
2018
18
Treating actinic keratosis: assessment of effectiveness, discomfort, costs and follow-up. ( 29441544 )
2018
19
Daylight-Mediated Photodynamic Therapy With Methyl Aminolevulinate in Actinic Keratosis Treatment. ( 29351725 )
2018
20
The challenge of diagnosing seborrheic keratosis by reflectance confocal microscopy. ( 29797357 )
2018
21
A novel frameshift SERPINB7 mutation in a Chinese case with Nagashima-type palmoplantar keratosis: case report and review of the literature. ( 29888455 )
2018
22
Borst-Jadassohn phenomenon arising from a seborrhoeic keratosis and its characteristic dermoscopic features. ( 29888802 )
2018
23
Melanoma in situ mimicking a Lichen planus-like keratosis. ( 29350666 )
2018
24
Energy-based devices for actinic keratosis field therapy. ( 29894524 )
2018
25
Teledermatology-driven topical therapy of actinic keratosis: a comparative study of clinical effectiveness and compliance. ( 29797670 )
2018
26
Swiss (German) Version of the Actinic Keratosis Quality of Life questionnaire. ( 29669340 )
2018
27
Validity and Reliability of the Dutch Adaptation of the Actinic Keratosis Quality of Life Questionnaire (AKQoL). ( 29909413 )
2018
28
Daylight Photodynamic Therapy Versus 5-Fluorouracil for the Treatment of Actinic Keratosis: A Case Series. ( 29322431 )
2018
29
Treatment of Actinic Keratosis with Photodynamic Therapy Using Red or Green Light: A Comparative Study. ( 29963684 )
2018
30
Field-change actinic keratosis and immunosuppression: therapeutic options. ( 29668097 )
2018
31
Effectiveness and safety of 0.5% colchicine cream versus photodynamic therapy with methyl aminolevulinate in the treatment of actinic keratosis and skin field cancerisation of the forearms: a randomized controlled trial. ( 29862491 )
2018
32
Detection of human papillomavirus in actinic keratosis. ( 29383738 )
2018
33
Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis. ( 29442526 )
2018
34
Artemether for Topical Use in Patients with Seborrheic Keratosis. ( 29957837 )
2018
35
Actinic Keratosis and Non-Invasive Diagnostic Techniques: An Update. ( 29316678 )
2018
36
Daylight photodynamic therapy: experience in the treatment of actinic keratosis in San Gallicano Institute of Rome and a review of literature. ( 29368865 )
2018
37
Tracking actinic keratosis of face and scalp treated with 0.015% ingenol mebutate to identify clinical and dermoscopic predictors of treatment response. ( 29356164 )
2018
38
Keratosis Punctata of the Palmar Creases. ( 29968049 )
2018
39
A follow-up report of acral melanoma in a patient with Nagashima-type palmoplantar keratosis: validation of SERPINB7 mutation and local recurrence. ( 29888704 )
2018
40
Diclofenac Sodium 3% in Hyaluronic Acid 2.5% Gel Significantly Diminishes the Actinic Keratosis Area and Severity Index. ( 29791916 )
2018
41
Effect of ingenol mebutate on actinic keratosis in a Korean population: A prospective clinical, dermoscopic and histopathological study from a single center. ( 30260493 )
2018
42
Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. ( 30267719 )
2018
43
Evaluation of the treatment costs and duration of topical treatments for multiple actinic keratosis based on the area of the cancerization field and not on the number of lesions. ( 30288788 )
2018
44
A Natural History of Actinic Keratosis and Cutaneous Squamous Cell Carcinoma Microbiomes. ( 30301852 )
2018
45
Full face ingenol mebutate for actinic keratosis: patient perspective. ( 30302750 )
2018
46
Conjunctival actinic keratosis. ( 30314825 )
2018
47
Claudin-1 expression decreases with increasing pathological grade in actinic keratosis and may be a marker of high-risk actinic keratosis. ( 30315595 )
2018
48
Monitoring treatment response in patients affected by actinic keratosis: Dermoscopic assessment and metalloproteinases evaluation after piroxicam 0.8% and sunfilter cream. ( 30318747 )
2018
49
Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice. ( 30323610 )
2018
50
Use and Cost of Actinic Keratosis Destruction in the Medicare Part B Fee-for-Service Population, 2007 to 2015. ( 30326488 )
2018

Variations for Keratosis

Expression for Keratosis

Search GEO for disease gene expression data for Keratosis.

Pathways for Keratosis

GO Terms for Keratosis

Cellular components related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 9.43 DSP FLG GJA1 KRT1 KRT10 KRT9
2 connexin complex GO:0005922 9.37 GJA1 GJB2
3 lateral plasma membrane GO:0016328 9.33 DSG1 GJA1 GJB2
4 fascia adherens GO:0005916 9.26 DSP GJA1
5 cornified envelope GO:0001533 9.1 DSG1 DSP FLG IVL KRT1 KRT10
6 cytosol GO:0005829 10.1 AAGAB DSG1 FLG GJA1 GJB2 IVL

Biological processes related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.63 DSG1 DSP IVL KRT1 KRT10 KRT9
2 epidermis development GO:0008544 9.58 ATP2A2 DSP KRT9
3 keratinocyte differentiation GO:0030216 9.56 DSP FLG IVL KRT10
4 decidualization GO:0046697 9.48 GJA1 GJB2
5 establishment of skin barrier GO:0061436 9.46 FLG KRT1
6 intermediate filament organization GO:0045109 9.43 DSP KRT9
7 gap junction assembly GO:0016264 9.37 GJA1 GJB2
8 peptide cross-linking GO:0018149 9.35 DSP FLG IVL KRT1 KRT10
9 epididymis development GO:1905867 9.32 GJA1 GJB2
10 cornification GO:0070268 9.17 DSG1 DSP FLG IVL KRT1 KRT10

Molecular functions related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.35 DSP FLG IVL KRT1 KRT10
2 gap junction channel activity GO:0005243 9.16 GJA1 GJB2
3 structural constituent of epidermis GO:0030280 8.8 FLG KRT1 KRT10

Sources for Keratosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....